Longeveron Inc. (LGVN)
Largest Insider Buys in Sector
LGVN Stock Price History Chart
LGVN Stock Performance
About Longeveron Inc.
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left …
Insider Activity of Longeveron Inc.
Over the last 12 months, insiders at Longeveron Inc. have bought $734,300 and sold $0 worth of Longeveron Inc. stock.
On average, over the past 5 years, insiders at Longeveron Inc. have bought $498,868 and sold $1.01M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Hare Joshua (Chief Scientific Officer) — $350,000. Soffer Rock (director) — $325,000. Baluch Khoso (director) — $28,513.
The last purchase of 42,553 shares for transaction amount of $100,000 was made by Hare Joshua (Chief Scientific Officer) on 2024‑04‑11.
List of Insider Buy and Sell Transactions, Longeveron Inc.
| 2024-04-11 | Chief Scientific Officer | 42,553 1.9683% | $2.35 | $100,000 | -1.24% | |||
| 2024-04-11 | director | 31,915 1.4762% | $2.35 | $75,000 | -1.24% | |||
| 2024-04-11 | Chief Executive Officer | 10,638 0.4921% | $2.35 | $24,999 | -1.24% | |||
| 2024-04-10 | Chief Scientific Officer | 106,383 4.4178% | $2.35 | $250,000 | -11.11% | |||
| 2024-04-10 | director | 106,383 4.4178% | $2.35 | $250,000 | -11.11% | |||
| 2024-01-10 | director | 5,000 0.0205% | $1.31 | $6,545 | -80.86% | |||
| 2023-12-29 | director | 8,322 0.0349% | $1.43 | $11,915 | -81.36% | |||
| 2023-12-28 | director | 10,000 0.0392% | $1.35 | $13,500 | -81.65% | |||
| 2023-12-28 | director | 1,678 0.0068% | $1.40 | $2,342 | -81.65% | |||
| 2023-09-12 | Sale | Chief Executive Officer | 13,405 0.0782% | $3.00 | $40,215 | -78.56% | ||
| 2023-09-12 | Chief Financial Officer | 5,000 0.0292% | $3.00 | $15,000 | -78.56% | |||
| 2023-09-08 | Sale | Chief Scientific Officer | 50,000 0.294% | $3.00 | $150,000 | -78.19% | ||
| 2023-09-07 | Sale | Chief Scientific Officer | 15,400 0.0906% | $3.00 | $46,200 | -78.08% | ||
| 2023-09-06 | Sale | Chief Scientific Officer | 17,700 0.1072% | $3.00 | $53,100 | -77.50% | ||
| 2023-09-01 | Sale | Chief Scientific Officer | 196,510 1.0361% | $3.00 | $589,530 | -79.92% | ||
| 2023-08-31 | Sale | Chief Scientific Officer | 24,924 0.1257% | $3.00 | $74,772 | -81.14% | ||
| 2023-08-25 | Sale | Chief Scientific Officer | 30,000 0.1635% | $3.00 | $90,000 | -79.38% | ||
| 2023-06-29 | Sale | CFO and Treasurer | 5,000 0.0246% | $3.51 | $17,550 | -59.88% | ||
| 2023-06-28 | Sale | CFO and Treasurer | 10,000 0.0475% | $3.43 | $34,300 | -59.91% | ||
| 2023-06-27 | Sale | CFO and Treasurer | 8,532 0.0415% | $3.48 | $29,691 | -59.12% |
Insider Historical Profitability
| Hare Joshua | Chief Scientific Officer | 633280 4.4102% | $1.97 | 6 | 10 | +68.44% |
| Soffer Rock | director | 208534 1.4522% | $1.97 | 6 | 1 | +61.88% |
| Hashad Mohamed Wa'el Ahmed | Chief Executive Officer | 19616 0.1366% | $1.97 | 1 | 1 | |
| PFEFFER JEFFREY | director | 15000 0.1045% | $1.97 | 1 | 0 | |
| Baluch Khoso | director | 15000 0.1045% | $1.97 | 2 | 0 |